Updates on Pipeline Developments, Facility Expansions, and Conference Calls - Research Report on Merck, UnitedHealth, Amgen, Baxter, and Charles River Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, September 27, 2013 NEW YORK, September 27, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), UnitedHealth Group Inc. (NYSE: UNH), Amgen, Inc. (NASDAQ: AMGN), Baxter International Inc. (NYSE: BAX), and Charles River Laboratories (NYSE: CRL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Merck & Co. Inc. Research Report On September 23, 2013, Merck & Co. Inc. (Merck) announced that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) for the resubmission of the New Drug Application for sugammadex sodium injection, the Company's investigational medicine for the reversal of neuromuscular blockade induced by rocoronium or vecuronium. Merck also stated that the FDA's letter brought forth some concerns regarding the operational aspects of a hypersensitivity study that the agency had requested in 2008. David Michelson, M.D., Head of Global Neuroscience Clinical Development, Merck Research Laboratories, said, "We believe sugammadex is an important innovation, and will work closely with the FDA to bring this product to hospitals, surgeons, anesthesia professionals and patients in the United States." The Company further reported that it is evaluating the Complete Response Letter and expects to determine a path forward in the near future. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/MRK] -- UnitedHealth Group Inc. Research Report On September 24, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that the Company will release its Q3 2013 financial results on October 17, 2013, before the market opens. The Company's President and CEO Stephen J. Hemsley will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors. In a separate release on July 18, 2013, the Company reaffirmed its full-year FY 2013 revenue guidance of approximately $122 billion and tightened its full-year FY 2013 net earnings to a range of $5.35 to $5.50 per share. According to Thomson Reuters I/B/E/S, analysts are expecting UnitedHealth to report revenue of $122.5 billion and EPS of $5.44 in full-year FY 2013. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/UNH] -- Amgen, Inc. Research Report On September 24, 2013, Amgen, Inc. (Amgen) announced that it has entered into a memorandum of understanding (MOU) with ShanghaiTech University to form a strategic partnership for the advancement of biopharmaceutical discovery and translational research in China. Under the agreement, Amgen plans to open a China research and development (R&D) center at ShanghaiTech University. Further, under the terms of the MOU, Amgen will co-locate its China R&D Center with ShanghaiTech University's two life science institutes: the Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and the iHuman Institute. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, said, "Amgen and ShanghaiTech University share mutual goals of scientific excellence and rigor and will benefit from each other's strength and expertise in advancing biopharmaceutical discovery in China. Expansion into China is a business priority for Amgen and opening this R&D center is another clear and important step forward in Amgen's commitment to the China market." Amgen stated that it expects the China R&D center to be fully operational in 2014. The Full Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/AMGN] -- Baxter International Inc. Research Report On September 19, 2013, Baxter International Inc. (Baxter) announced that the Company voluntarily recalled two of its Dual Luer Lock Caps (Product Code 2C6250, Lots 10043 and 10044) because of the presence of loose particulate matter found in the packaging. The Company stated that particulate matter entering the fluid path from the Luer Lock Caps may result in thrombotic and embolic events, which include pulmonary embolism, myocardial infarction and stroke. The Company has not received any complaints regarding the issue, but maintains that embolic events may not be easily attributed to such particulate matter. Baxter further informed that it has identified and resolved the root cause of the issue, and the financial impact of the recall is not material. Baxter reported that the US FDA categorized this as a Class I recall. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/BAX] -- Charles River Laboratories Research Report On September 12, 2013, Charles River Laboratories (Charles River) announced that it is relocating its European endotoxin and microbial detection services to a larger facility in Ecully, France. The Company stated that its new site offers a full range of both rapid microbiology systems based on the Endosafe cartridge technology for endotoxin testing and Accugenix microbial identification services. In addition, the Company announced the opening of the Charles River Accugenix contract laboratory service in Seoul, South Korea. According to Charles River, this new location will initially offer DNA-based sequencing of microorganisms, and will provide access to the Company's leading library databases. The Full Research Report on Charles River Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-25/CRL] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. InvestorsReports.com SOURCE Investors' Reports Contact: Kristi Saunders, +1-315-982-6420 (North America)
Updates on Pipeline Developments, Facility Expansions, and Conference Calls - Research Report on Merck, UnitedHealth, Amgen,
Press spacebar to pause and continue. Press esc to stop.